Natixis Kinnate Biopharma Inc. Transaction History

Natixis

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 13, 2022	SELL	$7.73 - $17.99 $5.2 Million - $12.1 Million	-672,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $11.1 Million - $17.1 Million	672,500 New	672,500 $11.9 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.